Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

Journal: Journal of the National Cancer Institute
PMID: 29546343

Abstract

BACKGROUND: Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with chemotherapy-induced ovarian function failure. The current analysis reports on endocrine data of patients with chemotherapy-induced ovarian function failure who were included in the phase III DATA study assessing different durations of adjuvant anastrozole after tamoxifen.

Authors

  • Irene E G van Hellemond
    Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Ingeborg J H Vriens
    Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Petronella G M Peer
    Biostatistics, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Astrid C P Swinkels
    Clinical Research Department, Netherlands Comprehensive Cancer Organisation IKNL, Utrecht, the Netherlands.
  • Carolien H Smorenburg
    Department of Internal Medicine, Medical Center Alkmaar, Alkmaar, the Netherlands.
  • Caroline M Seynaeve
    Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Maurice J C van der Sangen
    Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Judith R Kroep
    Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • Hiltje de Graaf
    Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
  • Aafke H Honkoop
    Department of Medical Oncology, Isala Clinics, Zwolle, the Netherlands.
  • Frans L G Erdkamp
    Department of Medical Oncology, Zuyderland Medical Center, Sittard, the Netherlands.
  • Franchette W P J van den Berkmortel
    Department of Medical Oncology, Zuyderland Medical Center, Heerlen, the Netherlands.
  • Jos J E M Kitzen
    Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Maaike de Boer
    Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Wïlfred K de Roos
    Department of Surgery, Gelderse Vallei Hospital, Ede, the Netherlands.
  • Sabine C Linn
    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Alexander L T Imholz
    Department of Medical Oncology, Deventer Hospital, Deventer, the Netherlands.
  • Vivianne C G Tjan-Heijnen
    Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.

Keywords

External Resources

Popular Topics
Recent Journals